Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines

Blood

Volumn 88, Issue 1, 1996, Pages 202-210

  Disis, Mary L ^a   Bernhard, Helga ^b   Shiota, Faith M ^b   Hand, Susan L ^b   Gralow, Julie R ^b   Huseby, Eric S ^b   Gillis, Steven ^b   Cheever, Martin A ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ONCOPROTEIN; TETANUS TOXOID; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; HUMORAL IMMUNITY; IMMUNOREGULATION; INTRADERMAL DRUG ADMINISTRATION; NONHUMAN; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 0029987485     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.1.202.202     Document Type: Article

References (27)

1. Pardoll DM: A new look for the 1990s. Nature 369:357, 1994
2. Houghton AN: Cancer antigens: Immune recognition of self and altered self. J Exp Med 180:1, 1994
3. Milich DR: Synthetic peptides: Prospects for vaccine development. Semin Immunol 2:307, 1990
4. Arnon R, Horwitz RJ: Synthetic peptides as vaccines. Curr Opin Immunol 4:449, 1992
5. Claassen E, de Leeuw W, de Greeve P, Hedriksen C, Boersma W: Freund's complete adjuvant: An effective but disagreeable formula. Res Immunol 143:478, 1992
6. Edelman R: An update on adjuvants in clinical trial. AIDS Res Hum Retrovirus 8:1409, 1992
7. Allison AC: Adjuvants and immune enhancement. Int J Technol Assess Health Care 10:107, 1994
8. Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S: Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen presenting cells. J Immunol 139:1113, 1987
9. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539, 1993
10. + progenitors in human bone marrow. J Immunol 149:2681, 1992
11. Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM: Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res 53:5841, 1993
12. Disis ML, Grolow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA: Peptide based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J Immunol 1996 (in press).
13. 't Hart BA, Kraakman E, Jonker M: An ear swelling reaction for in vivo monitoring of inflammatory T cell activity in collagen-arthritic rats. J Immunol Methods 176:179, 1994
14. Zecher R, Scheicher C, Wagener S, Reske-Kunz AB, Reske K: Modulation of accessory cell function of immortalized bone marrow-derived macrophages by granulocyte/macrophage colony-stimulating factor. Med Microbiol Immunol Berl 182:153, 1993
15. Gosselin EJ, Wardwell K, Rigby WF, Guyre PM: Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol 151:1482, 1993
16. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258, 1992
17. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271, 1991
18. Kato T, Inaba K, Ogawa Y, Inaba M, Kakihara K, Shimizu S, Ikehara S, Sudo T, Muramatsu S: Granulocyte-macrophage colony-stimulating factor enhances macrophage accessory function in con A-stimulated T-cell proliferation. Cell Immunol 130:490, 1990
19. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 55:1099, 1995
20. Flamand V, Sornasse T, Thielemans K, Demanet C, Leo O, Urbain J, Moser M: Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma. Adv Exp Med Biol 329:611, 1993
21. Stern AC, Jones TC: The side-effect profile of GM-CSF. Infection 2:S124, 1992
22. Armitage JO: The use of granulocyte-macrophage colony-stimulating factor in bone marrow transplantation. Semin Hematol 29:14, 1992
23. Kaplan G, Walsh G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, Barker J, Frindt PA, Fajardo TT, Celona R: Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175:1717, 1992
24. Streilein JW, Grammer SF: In vitro evidence that Langerhans cells can adopt two functionally distinct forms capable of antigen presentation to T lymphocytes. J Immunol 143:3925, 1989
25. Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone AM, Fathman CG, Inaba K, Steinman RM: Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 169:1169, 1989
26. Chen TT, Levy R: Induction of autoantibody responses to GM-CSF by hyperimmunization with an id-GM-CSF fusion protein. J Immunol 154:3105, 1995
27. Ragnhammar P, Friesen HJ, Frodin JE, Lefvert AK, Hassan M, Osterborg A, Mellstedt H: Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84:4078, 1994